BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Abuduwaili W, Wang X, Huang AT, Sun JL, Xu RC, Zhang GC, Liu ZY, Wang F, Zhu CF, Liu TT, Dong L, Zhu JM, Weng SQ, Li Y, Shen XZ. Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022. [PMID: 35951459 DOI: 10.1021/acsami.2c07247] [Reference Citation Analysis]
2 Chen G, Chen H, Huang X, Cheng S, Zheng S, Wu Y, Zheng T, Chen X, Guo X, Zhang Z, Xie X, Zhang B. Recurrence Outcome in Hepatocellular Carcinoma within Milan Criteria Undergoing Microwave Ablation with or without Transarterial Chemoembolization. Medicina 2022;58:1016. [DOI: 10.3390/medicina58081016] [Reference Citation Analysis]
3 Bai H, Meng S, Xiong C, Liu Z, Shi W, Ren Q, Xia W, Zhao X, Jian J, Song Y, Ni C, Gao X, Li Z. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2022. [PMID: 35896687 DOI: 10.1007/s00270-022-03221-z] [Reference Citation Analysis]
4 Yang X, Sun Y, Li D, Xu G, Huang X. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Front Immunol 2022;13:940009. [DOI: 10.3389/fimmu.2022.940009] [Reference Citation Analysis]
5 Lun Y, Zhou Y, Li Q, Chen P, Huang Y, Ye G. Preparation and characterization of a magnetic microsphere synthesized from sucrose allyl ether for transcatheter arterial embolization. Materials Today Chemistry 2022;24:100772. [DOI: 10.1016/j.mtchem.2022.100772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Falette Puisieux M, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, Soyer P, Coriat R. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers (Basel) 2022;14:2357. [PMID: 35625962 DOI: 10.3390/cancers14102357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ge C, Guan L, Wei W. How to improve the clinical teaching effectively in the mechanism of transarterial chemoembolilzation of hepatocellular carcinoma. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2022.03.052] [Reference Citation Analysis]
8 Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022;75:1257-74. [PMID: 34918361 DOI: 10.1002/hep.32241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liu Q, Xu X, Sun W. Down-regulated HSA_circ_0003528 inhibits hepatocellular carcinoma aggressiveness via the miR-212-3p/XIAP axis. Bioengineered 2022;13:11269-80. [PMID: 35484994 DOI: 10.1080/21655979.2022.2066046] [Reference Citation Analysis]
10 Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
11 Lei HW, Huang BR, Cai J, Li CM, Shang CB, Liao ZY, Wan ZD. CXCR4 antagonist AMD3100 enhances therapeutic efficacy of transcatheter arterial chemoembolization in rats with hepatocellular carcinoma. Kaohsiung J Med Sci 2022. [PMID: 35467082 DOI: 10.1002/kjm2.12540] [Reference Citation Analysis]
12 Chen S, Yang Y, Jiao Y, Hou L, Chang H, Liu S, Yan Z, Rajakani K. Efficacy of Drug-Eluting Bead Transarterial Chemoembolization in the Treatment of Colorectal Cancer Liver Metastasis. Journal of Healthcare Engineering 2022;2022:1-5. [DOI: 10.1155/2022/4930047] [Reference Citation Analysis]
13 Chen M, Li J, Shu G, Shen L, Qiao E, Zhang N, Fang S, Chen X, Zhao Z, Tu J, Song J, Du Y, Ji J. Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01385-x] [Reference Citation Analysis]
14 Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, Zhou J, Zhu K. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol 2022;13:848387. [PMID: 35300325 DOI: 10.3389/fimmu.2022.848387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wang W, Hao LP, Song H, Chu XY, Wang R. The Potential Roles of Exosomal Non-Coding RNAs in Hepatocellular Carcinoma. Front Oncol 2022;12:790916. [PMID: 35280805 DOI: 10.3389/fonc.2022.790916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 He F, Chen G, He R, Huang Z, Li J, Wu W, Chen J, Tang Y, Li D, Pan S, Feng Z, Dang Y. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ 2022;10:e12944. [DOI: 10.7717/peerj.12944] [Reference Citation Analysis]
17 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Reference Citation Analysis]
18 Song J, Zhou H, Gu D, Xu Y. Hepatocellular Carcinoma Differentiation: Research Progress in Mechanism and Treatment. Front Oncol 2021;11:790358. [PMID: 35096588 DOI: 10.3389/fonc.2021.790358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tang Y, Wu Y, Xue M, Zhu B, Fan W, Li J, Granito A. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/3822773] [Reference Citation Analysis]
20 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
21 Li T, Shi Q, Liu J, Wang Y, Zhou C, Wang C, Ju S, Huang S, Yang C, Chen Y, Bai Y, Xiong B. Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization. J Hepatocell Carcinoma 2021;8:1525-35. [PMID: 34888263 DOI: 10.2147/JHC.S337097] [Reference Citation Analysis]
22 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
23 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
24 Kang H, Lee HW. Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. Int J Gastrointest Interv 2021;10:183-8. [DOI: 10.18528/ijgii210046] [Reference Citation Analysis]
25 Tang J, Huang Z, Xu J, Lv Q, Wang P. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. Clin Res Hepatol Gastroenterol 2021;:101814. [PMID: 34597848 DOI: 10.1016/j.clinre.2021.101814] [Reference Citation Analysis]
26 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Fang S, Lai L, Zhu J, Zheng L, Xu Y, Chen W, Wu F, Wu X, Chen M, Weng Q, Ji J, Zhao Z, Tu J. A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation. Front Mol Biosci 2021;8:662366. [PMID: 34532340 DOI: 10.3389/fmolb.2021.662366] [Reference Citation Analysis]
28 Zhang H, Zhao X, Yu W. Factors Associated with Recurrence of Hepatocellular Carcinoma in 197 Patients Following Transarterial Chemoembolization: A Retrospective Study from a Single Center. Med Sci Monit 2021;27:e929879. [PMID: 34531359 DOI: 10.12659/MSM.929879] [Reference Citation Analysis]
29 Wang Y, Zhou C, Liu J, Shi Q, Huang S, Yang C, Li T, Chen Y, Xiong B. Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6935-41. [PMID: 34522136 DOI: 10.2147/CMAR.S328812] [Reference Citation Analysis]
30 Saito N, Tanaka T, Minamiguchi K, Taiji R, Nishiofuku H, Matsumoto T, Hirai T, Kichikawa K, Kawahara N, Matsuda D, Akiyama I. Ultrasonic Heating Detects Lipiodol Deposition within Liver Tumors after Transarterial Embolization: An In Vivo Approach. Biology (Basel) 2021;10:901. [PMID: 34571777 DOI: 10.3390/biology10090901] [Reference Citation Analysis]
31 Choi JW, Lee SY, Cho EJ, Jeong DI, Kim DD, Kim HC, Cho HJ. Gas generating microspheres for immediate release of Hsp90 inhibitor aiming at postembolization hypoxia in transarterial chemoembolization therapy of hepatocellular carcinoma. Int J Pharm 2021;607:120988. [PMID: 34389420 DOI: 10.1016/j.ijpharm.2021.120988] [Reference Citation Analysis]
32 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]